Evidence map›Paper›PMID 27059363›Full record

ArticleMedical oncology (Northwood, London, England)2016

Peptide receptor radionuclide therapy for metastatic paragangliomas.

David J Pinato, James R M Black, Ramya Ramaswami, Tricia M Tan, Delali Adjogatse, Rohini Sharma

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Response to targeted radionuclide therapy with [Frontiers in endocrinology · 2022
    Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. LutatheraPharmaceutics · 2023
    Review
  13. Efficacy and Safety of [Biomedicines · 2023
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

David J PinatoDivision of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W120HS, UK.
James R M BlackDivision of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W120HS, UK.
Ramya RamaswamiDepartment of Medical Oncology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W120HS, UK.
Tricia M TanDivision of Diabetes, Endocrinology and Metabolism, Department of Investigative Medicine, Imperial College London, London, UK.
Delali AdjogatseDepartment of Medical Oncology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W120HS, UK.
Rohini SharmaDivision of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W120HS, UK. r.sharma@imperial.ac.uk.
Imperial College London · GBHammersmith Hospital · GB

Funding

Medical Research Council MR/N020782/1
6 · The paper itself

Abstract

There is little evidence to direct the management of malignant paragangliomas (mPGL) beyond initial surgical treatment. Peptide receptor radionuclide therapy (PRRT), using somatostatin analogues, is effective in other neuroendocrine tumours, but data on its efficacy in treating mPGL are scarce. We report safety and efficacy outcomes from a case series of five patients with advanced mPGLs treated with (177)Lu-DOTATATE PRRT. The mean age of our cohort was 34 years (range 16-47); 4 patients were male with bone disease being the most prevalent metastatic site. PRRT scheme varied between 1 and 4 cycles, with premature cessation due to suspected pneumonitis in one case and disease progression in another. Three patients with previously documented progressive disease achieved stabilization following treatment; one had partial response and one was treatment refractory. Median progression-free survival was 17 months (range 0-78 months). 177-Lu-DOTATATE is an effective therapy in mPGLs in this molecularly defined patient cohort, warranting further investigation in larger studies including hereditary and sporadic mPGL.

Indexed as

AdolescentAdultFemaleHumansKaplan-Meier EstimateLutetiumMaleMiddle AgedOctreotideOrganometallic CompoundsParagangliomaRadioisotopesRadiotherapyTreatment OutcomeLutetiumlutetium Lu 177 dotatateOctreotideOrganometallic CompoundsRadioisotopesMalignant paragangliomaManagementPeptide receptor radionuclide therapySurvival

Identifiers

PMID27059363
OpenAlexW2332637465

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.